CALML4 Antibody

What is CALML4 and what are its key molecular characteristics?

CALML4 (Calmodulin-Like Protein 4) is an EF-hand calcium-binding protein that shares structural similarities with calmodulin. It has a calculated molecular weight of approximately 22 kDa, though the observed molecular weight in experimental conditions typically ranges from 22-25 kDa as detected in Western blot applications . The protein consists of 196 amino acids and is encoded by the CALML4 gene (Gene ID: 91860), which is mapped to chromosome location 15q23. CALML4 has been identified in multiple databases including UniProt (Primary AC: Q96GE6), with several secondary accession numbers (B4DL15, F8W6Y4, Q6MZY3, Q6N048, Q9H286) indicating various isoforms or database entries . The protein has also been identified as a serologically defined breast cancer antigen NY-BR-20, suggesting potential roles in cancer biology .

What types of CALML4 antibodies are currently available for research?

Current research-grade CALML4 antibodies are primarily polyclonal antibodies raised in rabbits against various immunogens including full-length CALML4 protein and specific protein fragments . These antibodies are available in multiple formats:

• Unconjugated primary antibodies suitable for applications including Western blot, immunoprecipitation, and immunofluorescence

• Conjugated antibodies, such as FITC-labeled CALML4 antibodies for flow cytometry and fluorescence microscopy applications

The antibodies show validated reactivity across multiple species, with most commercial products demonstrating affinity for human, mouse, and rat CALML4 proteins, making them versatile tools for comparative studies across these model organisms .

What are the recommended applications for CALML4 antibodies?

CALML4 antibodies have been validated for multiple research applications as outlined below:

For optimal results, researchers should perform antibody titration experiments to determine the ideal concentration for their specific experimental system and sample type . The antibodies have been successfully used in multiple published studies, particularly for Western blot and immunofluorescence applications .

How should CALML4 antibodies be stored and handled to maintain optimal activity?

CALML4 antibodies require specific storage and handling conditions to maintain their immunoreactivity and specificity. The antibodies should be stored at -20°C where they remain stable for approximately 12 months after shipment . To prevent protein degradation during storage:

• Aliquot the antibody solution upon receipt to avoid repeated freeze-thaw cycles, which can significantly reduce antibody activity

• Store in the buffer provided by the manufacturer, typically PBS (pH 7.3) containing 0.02% sodium azide and 50% glycerol

• Some preparations may contain 0.1% BSA for additional stability in smaller volume formats (e.g., 20μL sizes)

When working with the antibody, thaw aliquots completely at room temperature before use and gently mix by pipetting or flicking the tube, avoiding vigorous vortexing which can cause protein denaturation. Once thawed, keep the antibody on ice during experimental setup to maintain stability .

What are the recommended Western blot protocols for CALML4 detection?

For optimal Western blot detection of CALML4, follow these methodological guidelines:

• Sample Preparation:

  • Prepare tissue or cell lysates in standard RIPA or NP-40 lysis buffer containing protease inhibitors

  • Denature samples in reducing sample buffer (containing β-mercaptoethanol or DTT) at 95°C for 5 minutes

• Gel Electrophoresis:

  • Resolve 20-40 μg of total protein on a 12-15% SDS-PAGE gel (ideal for separating proteins in the 22-25 kDa range)

• Transfer and Blocking:

  • Transfer proteins to PVDF or nitrocellulose membrane

  • Block membrane with 5% non-fat milk or 3-5% BSA in TBST for 1 hour at room temperature

• Primary Antibody Incubation:

  • Dilute CALML4 antibody 1:500 - 1:2000 (for standard sensitivity) or up to 1:10000 (for high sensitivity applications) in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

• Detection:

  • Wash membrane 3-5 times with TBST

  • Incubate with HRP-conjugated secondary antibody (anti-rabbit IgG) for 1 hour at room temperature

  • Develop using chemiluminescence detection reagents and image using a digital imaging system

The expected band for CALML4 should appear at approximately 22-25 kDa. Additional bands may reflect isoforms, post-translational modifications, or proteolytic fragments .

How can I optimize immunofluorescence staining using CALML4 antibodies?

For successful immunofluorescence staining of CALML4, consider the following optimization steps:

• Fixation Method Selection:

  • For intracellular proteins like CALML4, use 4% paraformaldehyde fixation (10-15 minutes at room temperature) followed by permeabilization with 0.1-0.3% Triton X-100

  • Alternative fixation with ice-cold methanol (-20°C for 10 minutes) may better preserve certain epitopes

• Blocking and Antibody Dilution:

  • Block with 3% BSA in PBS for 30 minutes at room temperature to reduce non-specific binding

  • For primary antibody, start with 1:50 dilution for unconjugated antibodies, and adjust based on signal intensity

  • For FITC-conjugated antibodies, more dilute preparations (1:100-1:200) may be optimal to reduce background

• Controls and Visualization:

  • Include a negative control (secondary antibody only) to assess background

  • For co-localization studies, include appropriate markers for subcellular compartments

  • Counterstain nuclei with DAPI or Hoechst 33342 as demonstrated in published protocols

  • Image using a confocal microscope with appropriate filter settings (for FITC conjugates: excitation 499nm, emission 515nm)

• Signal Verification:

  • Consider using recombinant CALML4 protein fragments (such as the aa 130-196 fragment) for blocking experiments to confirm specificity of staining

  • Pre-incubate the antibody with 100x molar excess of the protein fragment for 30 minutes at room temperature before applying to samples

How can CALML4 antibodies be used to investigate protein-protein interactions?

CALML4 antibodies can be employed in multiple techniques to study protein-protein interactions:

• Co-Immunoprecipitation (Co-IP):

  • CALML4 antibodies have been validated for immunoprecipitation in mouse thymus tissue, making them suitable for Co-IP experiments

  • Use 0.5-4.0 μg of antibody per 1.0-3.0 mg of total protein lysate to pull down CALML4 and associated proteins

  • After IP, analyze the precipitated complexes by mass spectrometry or Western blot for suspected interaction partners

  • This approach can reveal physiological interactions between CALML4 and other proteins in calcium signaling pathways or other cellular processes

• Proximity Ligation Assay (PLA):

  • Combine CALML4 antibody with antibodies against suspected interaction partners

  • This technique provides visual confirmation of protein interactions when proteins are within 40nm of each other

  • Particularly useful for investigating transient interactions in intact cells

• Bimolecular Fluorescence Complementation (BiFC):

  • While not directly using the antibody, validation of interactions discovered through antibody-based methods can be confirmed using this approach

  • Results can be correlated with immunostaining using CALML4 antibodies

As demonstrated in research involving related calcium-binding proteins, these interaction studies can provide critical insights into CALML4's role in cellular signaling pathways and its functional relationships with other proteins .

What are the considerations for using CALML4 antibodies in knockout/knockdown validation studies?

When using CALML4 antibodies to validate knockout or knockdown models, researchers should implement the following methodological approach:

• Experimental Design:

  • Include appropriate control samples (wild-type, non-targeting siRNA, empty vector) alongside KO/KD samples

  • Process all samples identically to ensure comparable results

  • Consider analyzing multiple tissues/cell types as CALML4 expression may vary between tissues

• Validation Strategies:

  • Western blot: Use recommended dilutions (1:2000-1:10000) to detect presence/absence of CALML4 band at 22-25 kDa

  • Immunofluorescence: Compare staining patterns between wild-type and KO/KD samples

  • qPCR: Complement protein-level studies with mRNA analysis

• Data Interpretation:

  • Complete absence of signal in true knockouts versus partial reduction in knockdowns

  • Be aware of potential cross-reactivity with related proteins, especially other calmodulin-like proteins

  • Published applications indicate successful use of CALML4 antibodies in KD/KO validation studies

• Potential Pitfalls:

  • Compensatory upregulation of related proteins in knockout models

  • Incomplete knockout in some cell populations

  • Post-transcriptional regulation affecting correlation between mRNA and protein levels

This validation is critical for establishing the specificity of phenotypes observed in functional studies of CALML4 deletion or reduction .

How can CALML4 antibodies be used to investigate calcium-dependent signaling pathways?

CALML4, as a calcium-binding protein with EF-hand domains, likely plays roles in calcium-dependent signaling. Researchers can leverage CALML4 antibodies to investigate these pathways through several approaches:

• Calcium Modulation Studies:

  • Treat cells with calcium ionophores (ionomycin, A23187) or calcium chelators (BAPTA-AM, EGTA)

  • Use CALML4 antibodies in Western blot or IF to monitor potential changes in:

    • Protein expression levels

    • Subcellular localization

    • Post-translational modifications

    • Complex formation with other proteins

• Calmodulin-Dependent Kinase Pathway Analysis:

  • Research suggests connections between calmodulin-like proteins and CaMK signaling pathways

  • Investigate potential relationships between CALML4 and CaMKII or CaMKIV using co-immunoprecipitation followed by Western blot

  • Monitor phosphorylation of downstream targets like CREB after manipulating CALML4 levels

• Protease-Dependent Regulation:

  • Evidence indicates calmodulin-family proteins can be regulated by calcium-sensitive proteases like calpain

  • Design experiments with calpain inhibitors (ALLM, ALLN) to investigate whether CALML4 undergoes similar regulation

  • Compare CALML4 expression patterns in Western blots from samples with and without protease inhibitors

These approaches can provide insights into the functional roles of CALML4 in calcium signaling networks and its potential contributions to related pathologies when dysregulated .

What are common issues in Western blot detection of CALML4 and how can they be resolved?

Researchers may encounter several challenges when detecting CALML4 by Western blot:

• Weak or No Signal:

  • Potential causes: Insufficient antibody concentration, low CALML4 expression, protein degradation, inefficient transfer

  • Solutions:

    • Increase antibody concentration (try 1:500 instead of 1:2000)

    • Increase protein loading (50-100 μg total protein)

    • Use fresh lysates with complete protease inhibitor cocktail

    • Optimize transfer conditions for small proteins (22-25 kDa)

    • Consider using enhanced chemiluminescence detection systems

• Multiple Bands or Unexpected Band Size:

  • Potential causes: Cross-reactivity, protein degradation, post-translational modifications, splice variants

  • Solutions:

    • Verify antibody specificity using blocking peptides or recombinant protein controls

    • Pre-incubate antibody with 100x molar excess of recombinant CALML4 fragment

    • Use freshly prepared samples with protease inhibitors

    • Consider known CALML4 variants with potential altered molecular weights

• High Background:

  • Potential causes: Insufficient blocking, excessive antibody concentration, contaminated buffers

  • Solutions:

    • Increase blocking time or change blocking agent (try 5% BSA instead of milk)

    • Use more stringent washing conditions (increase TBST washing time and volume)

    • Further dilute primary and secondary antibodies

    • Filter all buffers before use

For optimal results, follow manufacturer-specific protocols as optimization parameters may vary between different CALML4 antibody products .

How can cross-reactivity issues with CALML4 antibodies be addressed and evaluated?

Cross-reactivity with related calcium-binding proteins is a potential concern when working with CALML4 antibodies. To address this issue:

• Experimental Validation of Specificity:

  • Perform blocking experiments using recombinant CALML4 protein fragments

  • In IHC/ICC and WB experiments, pre-incubate the antibody with 100x molar excess of the protein fragment control for 30 min at room temperature

  • Compare staining patterns between wild-type and CALML4 knockout/knockdown samples, if available

• Bioinformatic Analysis:

  • Assess sequence homology between CALML4 and related proteins (other calmodulin-like proteins)

  • Pay particular attention to the immunogen sequence used to generate the antibody

  • For polyclonal antibodies, recognize that different epitopes may show variable cross-reactivity

• Multi-technique Verification:

  • Confirm results using multiple detection methods (WB, IF, IP)

  • Corroborate protein expression with mRNA expression data when possible

  • Use multiple antibodies targeting different epitopes of CALML4 to confirm findings

• Species Considerations:

  • Note that CALML4 protein has varying degrees of sequence identity across species: approximately 81% between human and mouse/rat

  • Use species-appropriate positive controls to verify antibody performance in your experimental system

What are the challenges in detecting endogenous versus overexpressed CALML4 and how can they be overcome?

Detecting endogenous CALML4 presents different challenges compared to detecting overexpressed protein:

• Sensitivity Limitations for Endogenous Detection:

  • Challenge: Low natural expression levels in certain cell types or tissues

  • Solutions:

    • Enrich for CALML4 using immunoprecipitation before Western blot

    • Use higher antibody concentrations (1:500 rather than 1:2000) for endogenous detection

    • Employ signal amplification methods (TSA for immunostaining, enhanced chemiluminescence for WB)

    • Select tissues known to express CALML4 at higher levels (thymus, kidney) as positive controls

• Specificity Concerns with Overexpression:

  • Challenge: Artifacts due to non-physiological expression levels

  • Solutions:

    • Use inducible expression systems to control expression levels

    • Compare localization patterns between endogenous and tagged proteins

    • Validate functional studies with rescue experiments in knockout backgrounds

• Detection Strategy Differences:

  • For endogenous detection, more sensitive dilutions (1:500-1:1000) are typically required

  • For overexpressed protein, more dilute antibody preparations (1:5000-1:10000) may be optimal to prevent signal saturation

  • Consider using mouse/rat tissue samples (kidney, thymus) as positive controls, which have been validated for CALML4 detection

• Validation Approach:

  • Confirm antibody specificity using siRNA knockdown of endogenous protein

  • For overexpression studies, include empty vector controls processed identically

  • When studying tagged CALML4, compare results using both tag-specific and CALML4-specific antibodies

How can CALML4 antibodies be used to investigate disease associations?

CALML4 antibodies provide valuable tools for exploring potential disease associations, particularly in cancer research where CALML4 has been identified as a serologically defined breast cancer antigen (NY-BR-20) :

• Tissue Expression Analysis:

  • Use immunohistochemistry with CALML4 antibodies to compare expression patterns between normal and diseased tissues

  • Develop tissue microarrays to systematically evaluate CALML4 expression across multiple patient samples

  • Correlate expression levels with clinical parameters and outcomes

• Signaling Pathway Dysregulation:

  • Given the connection between calcium signaling and various pathologies, investigate CALML4's role in disease-associated signaling networks

  • Use co-immunoprecipitation with CALML4 antibodies followed by mass spectrometry to identify novel interaction partners in disease states

  • Compare phosphorylation status of downstream targets in normal versus diseased samples

• Therapeutic Target Validation:

  • Use CALML4 antibodies to monitor protein expression changes in response to experimental therapeutics

  • Evaluate CALML4 as a potential biomarker for disease progression or treatment response

  • For extracellular or membrane-associated CALML4, investigate potential applications of therapeutic antibodies

• Experimental Considerations:

  • Ensure appropriate controls (tissue-matched normal samples)

  • Consider the heterogeneity of disease tissues when interpreting staining patterns

  • Validate findings across multiple patient samples and experimental models

Research into calmodulin-dependent kinase signaling has already revealed connections to important cellular pathways, suggesting that CALML4 may similarly participate in disease-relevant processes .

What methodological approaches can be used to study post-translational modifications of CALML4?

Investigating post-translational modifications (PTMs) of CALML4 requires specialized approaches utilizing CALML4 antibodies:

• Phosphorylation Analysis:

  • Immunoprecipitate CALML4 using validated antibodies followed by:

    • Western blot with phospho-specific antibodies (if available)

    • Mass spectrometry analysis to identify phosphorylation sites

  • Compare phosphorylation patterns before and after cellular stimulation

  • Use phosphatase inhibitors during sample preparation to preserve phosphorylation status

• Calcium-Dependent Modifications:

  • As a calcium-binding protein, CALML4 may undergo conformational changes upon calcium binding

  • Compare immunoprecipitation efficiency under high vs. low calcium conditions

  • Investigate calcium-dependent interactions using co-immunoprecipitation in the presence of calcium chelators or calcium

• Proteolytic Processing:

  • Evidence from related proteins suggests calmodulin-family proteins may undergo calpain-mediated processing

  • Compare CALML4 banding patterns in Western blots from samples with and without protease inhibitors

  • Use N-terminal and C-terminal specific antibodies (if available) to detect potential cleavage products

• Other PTMs:

  • Immunoprecipitate CALML4 and analyze by mass spectrometry for:

    • Ubiquitination

    • SUMOylation

    • Acetylation

    • Methylation

  • Validate findings using specific inhibitors of PTM-regulating enzymes

These approaches can provide insights into how CALML4 function is regulated in different cellular contexts and how these regulatory mechanisms might be altered in disease states.

What are emerging technologies and approaches for studying CALML4 beyond traditional antibody applications?

Beyond conventional antibody applications, several emerging technologies offer new opportunities for CALML4 research:

• CRISPR-Based Approaches:

  • Generate CALML4 knockout cell lines for functional studies

  • Create endogenously tagged CALML4 (e.g., GFP-CALML4) for live-cell imaging without overexpression artifacts

  • Use CRISPRi/CRISPRa systems for titratable knockdown/upregulation

  • Validate these genetic models using established CALML4 antibodies

• Advanced Microscopy Techniques:

  • Super-resolution microscopy (STORM, PALM) using CALML4 antibodies for nanoscale localization

  • FRET/FLIM analysis to study CALML4 interactions with binding partners

  • Live-cell calcium imaging combined with CALML4 localization to correlate dynamics

  • Expansion microscopy to visualize CALML4 distribution in complex cellular structures

• Single-Cell Approaches:

  • Single-cell proteomics to examine CALML4 expression heterogeneity

  • Combine CALML4 immunostaining with single-cell transcriptomics for multi-omic analysis

  • Mass cytometry (CyTOF) incorporating CALML4 antibodies for high-dimensional analysis of signaling networks

• Protein Engineering:

  • Develop biosensors based on CALML4 structure to monitor calcium dynamics or protein interactions

  • Express recombinant CALML4 fragments for structural studies

  • Create synthetic antibody derivatives (nanobodies, affimers) for specialized applications

• Therapeutic Applications:

  • Investigate CALML4 as a potential diagnostic marker, particularly in breast cancer contexts

  • Explore the development of antibody-drug conjugates if CALML4 shows disease-specific expression patterns

  • Consider CALML4 pathway modulation as a therapeutic strategy

These advanced approaches, when combined with traditional antibody-based methods, can provide comprehensive insights into CALML4 biology and potential disease associations.